Elite in Uveal Melanoma

Dr. Marlana Orloff

Hematology | Oncology
Jefferson University Physicians
925 Chestnut St, Suite 3, 
Philadelphia, PA 
Offers Telehealth
17 Years of Experience
Elite in Uveal Melanoma
Jefferson University Physicians
925 Chestnut St, Suite 3, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marlana Orloff is a Hematologist and an Oncologist in Philadelphia, Pennsylvania. Dr. Orloff has been practicing medicine for over 17 years and is rated as an Elite provider by MediFind in the treatment of Uveal Melanoma. Her top areas of expertise are Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, Melanoma, and Liver Embolization.

Her clinical research consists of co-authoring 45 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 29 articles and participated in 5 clinical trials in the study of Uveal Melanoma.

Graduate Year
2009
Specialties
Hematology
Oncology
Hospital Affiliations
Thomas Jefferson University Hospital
Upmc Pinnacle Hospitals
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

JEFFERSON UNIVERSITY PHYSICIANS
925 Chestnut St, Suite 3, Philadelphia, PA 19107

Additional Areas of Focus

Dr. Orloff has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: APG-115+Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug, Other
Study Drug: Romidepsin
Study Phase: Phase 1
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination With Intravenous Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination With Intravenous Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2024
Intervention Type: Biological, Drug
Study Drugs: SD-101, Nivolumab, Ipilimumab
Study Phase: Phase 1
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Combination product
Study Drug: Melphalan/Hepatic Device System
Study Phase: Phase 3
View 6 Less Clinical Trials

45 Total Publications

Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients.
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients.
Journal: The oncologist
Published: March 24, 2025
Similar Doctors
Elite in Uveal Melanoma
Dr. Takami Sato
Hematology | Oncology
Elite in Uveal Melanoma
Dr. Takami Sato
Hematology | Oncology

Jefferson University Physicians

925 Chestnut St, Mezzanine, 
Philadelphia, PA 
 (0.1 miles away)
215-955-5050
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Takami Sato is a Hematologist and an Oncologist in Philadelphia, Pennsylvania. Dr. Sato is rated as an Elite provider by MediFind in the treatment of Uveal Melanoma. His top areas of expertise are Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, Liver Embolization, and Osteotomy.

Distinguished in Uveal Melanoma
Dr. Rino Seedor
Hematology | Oncology
Distinguished in Uveal Melanoma
Dr. Rino Seedor
Hematology | Oncology

Jefferson University Physicians

925 Chestnut St, 
Philadelphia, PA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rino Seedor is a Hematologist and an Oncologist in Philadelphia, Pennsylvania. Dr. Seedor is rated as a Distinguished provider by MediFind in the treatment of Uveal Melanoma. Her top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, and Melanoma of the Eye.

Advanced in Uveal Melanoma
Dr. Jessica O. Yang
Oncology | Hematology
Advanced in Uveal Melanoma
Dr. Jessica O. Yang
Oncology | Hematology

Memorial Sloan Kettering Cancer Center At Basking Ridge New Jersey

136 Mountainview Blvd, 
Basking Ridge, NJ 
 (56.3 miles away)
908-542-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jessica Yang is an Oncologist and a Hematologist in Basking Ridge, New Jersey. Dr. Yang is rated as an Advanced provider by MediFind in the treatment of Uveal Melanoma. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Stomach Cancer, Familial Pancreatic Cancer, and Pancreatic Cancer. Dr. Yang is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Orloff's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile